Systemic blood coagulation activation in acute coronary syndromes
Open Access
- 26 February 2009
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 113 (9), 2070-2078
- https://doi.org/10.1182/blood-2008-07-167411
Abstract
We evaluated systemic alterations to the blood coagulation system that occur during a coronary thrombotic event. Peripheral blood coagulation in patients with acute coronary thrombosis was compared with that in people with stable coronary artery disease (CAD). Blood coagulation and platelet activation at the microvascular injury site were assessed using immunochemistry in 28 non-anticoagulated patients with acute myocardial infarction (AMI) versus 28 stable CAD patients matched for age, sex, risk factors, and medications. AMI was associated with increased maximum rates of thrombin-antithrombin complex generation (by 93.8%; P < .001), thrombin B-chain formation (by 57.1%; P < .001), prothrombin consumption (by 27.9%; P = .012), fibrinogen consumption (by 27.0%; P = .02), factor (f) Va light chain generation (by 44.2%; P = .003), and accelerated fVa inactivation (by 76.1%; P < .001), and with enhanced release of platelet-derived soluble CD40 ligand (by 44.4%; P < .001). FVa heavy chain availability was similar in both groups because of enhanced formation and activated protein C (APC)–mediated destruction. The velocity of coagulant reactions in AMI patients showed positive correlations with interleukin-6. Heparin treatment led to dampening of coagulant reactions with profiles similar to those for stable CAD. AMI-induced systemic activation of blood coagulation markedly modifies the pattern of coagulant reactions at the site of injury in peripheral vessels compared with that in stable CAD patients.Keywords
This publication has 69 references indexed in Scilit:
- Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor compositionJournal of Thrombosis and Haemostasis, 2008
- Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene studyJournal of Thrombosis and Haemostasis, 2007
- Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actionsBlood, 2006
- Effects of simvastatin on angiogenic growth factors released at the site of microvascular injuryThrombosis and Haemostasis, 2006
- Thrombin generation in vascular tissueJournal of Thrombosis and Haemostasis, 2005
- The interactions between inflammation and coagulationBritish Journal of Haematology, 2005
- Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemiaThrombosis and Haemostasis, 2005
- Unique in Vivo Modifications of Coagulation Factor V Produce a Physically and Functionally Distinct Platelet-derived CofactorPublished by Elsevier ,2004
- Membrane-associated CD40L and sCD40L in atherothrombotic diseaseThrombosis and Haemostasis, 2003
- Heightened Thrombin Formation but Normal Plasma Levels of Activated Factor VII in Patients With Acute Coronary SyndromesArteriosclerosis, Thrombosis, and Vascular Biology, 1995